Circulating Resistin Levels and Risk of Colorectal Cancer: A Meta-Analysis

Abstract

Objectives. Published data on resistin levels in patients with colorectal cancer (CRC) were conflicting and heterogeneous. We conducted a meta-analysis of observational studies to examine the association of circulating resistin levels with carcinogenesis of the CRC. Methods. Potentially eligible studies published up to November 2015 were searched through MEDLINE, EMBASE, Science Citation Index Expanded database, CNKI, and WanFang database. The pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) calculated by fixed- or random-effect model were used to estimate the effects. Results. A total of 11 studies involving 965 patients were admitted in our meta-analysis. The pooled effects indicated that resistin levels were higher in CRC patients compared to healthy controls (WMD: 1.47 ng/mL; 95% CI: 0.78 to 2.16), with significant heterogeneity across the studies (I 2 = 72%, p < 0.0001). Subgroup analyses and sensitivity analyses revealed that study quality, design, sample type, and resistin assays may account for this heterogeneity. No publication bias was observed. Conclusions. Our meta-analysis suggests that increased circulating resistin levels are associated with greater risk of colorectal cancer. Given the limited number of available studies and significant heterogeneity, larger well-designed randomized studies are warranted.

Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine

“…In spite of still unresolved questions regarding the exact role of resistin in colorectal carcinogenesis, higher resistin levels in CRC are reported in large number of studies [18]. An association among tumor stage and serum resistin concentrations has been shown [30] and possible use of resistin as a marker for CRC was emphasized [39].…”

“…The same authors showed that resistin-CAP-1 interaction is highly capable to activate protein kinase A (PKA) and nuclear factor kappa B (NF-kB) signaling pathway, which further leads to inflammatory cytokines production [17]. High blood concentrations of resistin have often been associated with CRC [18], but CAP-1 gene expression was investigated in patients with cardiovascular diseases [19], while resistin-CAP-1 interaction is still unexplored in CRC. Yet, detection of plausible patterns of alterations in protein-receptor complex could be important for prediction of risk, prevention, and personalized treatment of CRC, as for any other malignant disease [20].…”

Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes

“…Elevated levels of resistin have been reported in several types of malignancies, including BC [13, 40, 41]. Further, the levels of resistin correlate with breast tumor size, stage and lymph node metastasis [25].…”

Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non–muscle-invasive Bladder Cancer

“…Moreover, it has been shown that ITAC-modified tumor cell vaccines can enhance antitumor immunity and reduce the incidence of disseminated metastasis (33). Resistin, an adipokine, has been suggested as a prognostic biomarker for breast and colorectal cancer with conflicting results (34,35). It is secreted from monocytes and macrophages and is involved in insulin resistance, inflammation, and cell signaling.…”